Key facts
- Raydiant Oximetry’s last known valuation is $27.0M (Feb 2026).
- It has raised $62.3M across 6 recorded rounds; the latest was Seed Round ($4.3M) in May 2024.
- Notable investors include US National Science Foundation, Enterprise Ireland, Impact Assets, MedTech Innovator, StartX (US) — 38 tracked in total.
- Raydiant Oximetry has filed 9 Form Ds with the SEC since 2018, most recently Jun 2024 ($4.3M sold to 32 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 6 rounds
- ·The complete investor list — 38 names
- ·Watchlist + deal alerts for Raydiant Oximetry
Funding rounds
6 roundsAbout Raydiant Oximetry
Developer of a non-invasive medical device designed to deliver healthy babies and prevent cesarean section issues. The company's device measures fetal oxygen levels during labor to facilitate improved outcomes for mothers and babies during childbirth and evaluates fetal oxygenation during labor, enabling clinicians to reduce the risk of birth injury and over-intervention as well as decrease healthcare costs and disparities.
- Sector
- Healthcare
- HQ
- San Ramon, CA, United States
- Founded
- 2016
- Employees
- 25
- Website
- raydiantoximetry.com/
- Ownership
- Privately Held (backing)
Raydiant Oximetry doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Raydiant Oximetry shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Raydiant Oximetry in its N-PORT filings yet. We sweep new filings monthly.